New gene therapy fights deadly brain tumors with a One-Two punch
NCT ID NCT07346144
First seen Jan 17, 2026 · Last updated May 15, 2026 · Updated 19 times
Summary
This trial tests a new gene therapy called TGX-007 for people with a fast-growing brain cancer called glioblastoma. The therapy uses a harmless virus to deliver two special instructions: one helps a common drug kill cancer cells, and the other wakes up the immune system to attack the tumor. About 68 adults aged 18-70 with newly diagnosed or returning tumors will receive a direct injection into the tumor, followed by a short course of an antiviral pill. The study aims to find the safest and most effective dose and see if it helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Hospital
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States
-
Royal Infirmary of Edinburgh
RECRUITINGEdinburgh, United Kingdom
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.